Breaking News Instant updates and real-time market news.

CRSP

Crispr Therapeutics

$17.07

0.36 (2.15%)

20:43
07/13/17
07/13
20:43
07/13/17
20:43

CRISPR Therapeutics initiated with a Hold at SunTrust

SunTrust analyst Peter Larson initiated CRISPR Therapeutics with a Hold and a $16 price target.

CRSP Crispr Therapeutics
$17.07

0.36 (2.15%)

03/28/17
CHDN
03/28/17
INITIATION
Target $23.5
CHDN
Buy
CRISPR Therapeutics initiated with a Buy at Chardan
Chardan analyst Madhu Kumar initiated CRISPR Therapeutics with a Buy and a $23.50 price target saying upside from clinical leadership in CRISPR therapy offsets any potential downside from its IP exposure.
02/16/17
PIPR
02/16/17
NO CHANGE
Target $21
PIPR
Overweight
Piper's Schimmer calls CRISPR selloff 'major overreaction'
Piper Jaffray analyst Joshua Schimmer views yesterday's selloff in shares of CRISPR Therapeutics (CRSP) as a "major overreaction." The stock closed yesterday down 8%, or $1.36, to $15.90 after the patent office did not allow the patent interference with UC Berkeley versus Broad Institute over a Crispr/Cas-9 patent. Now that it's deemed patentable, CRISPR will move forward to get its own claims issued and likely move towards a second interference, Schimmer tells investors in a research note. CRISPER and Intellia Therapeutics (NTLA) are essentially litigation partners against the Broad, and now have the chance to win by knocking out Editas Medicine's (EDIT) single-guide tracr patent or by showing it was the first to invent and reduce to practice the application in eukaryotes, the analyst contends. Schimmer says he can't understand why Editas' valuation is higher than CRISPR's. He believes it should be the opposite. The analyst keeps an Overweight rating on CRISPR with a $21 price target.
02/15/17
JEFF
02/15/17
NO CHANGE
JEFF
Patent ruling best case for Editas Medicine, says Jefferies
Jefferies analyst Gena Wang views the United States Patent and Trademark Office's judgment of "no interference-in-fact" for the CRISPR/Cas9 interference motion phase as the "best case" for Editas Medicine (EDIT), Broad Institute's licensee. The analyst sees three choices for The University of California, which has CRISPR Therapeutics (CRSP) and Intellia Therapeutics (NTLA) as licensees: Appeal, seek second interference, or discuss a settlement. Wang sees cross-licensing as the likely eventual path taken by both parties. CRISPR and Intellia could license from Editas the use of CRISPR in eukaryotic cells, while Editas could license from the two companies the use of single guide and tracrRNA, the analyst tells investors in a research note. She believes a royalty could be in the mid-single-digit range. Shares of Editas are up 33% to $24.99 in afternoon while CRISPR is down 13% to $15.05 and Intellia is down 11% to $12.26.
11/15/16
SBSH
11/15/16
INITIATION
Target $19
SBSH
Neutral
CRISPR Therapeutics initiated with a Neutral at Citi
Citi analyst Yigal Nochomovitz started CRISPR Therapeutics with a Neutral rating and $19 price target. The risk/reward is balanced with the stock up 25% since the initial public offering, Nochomovitz tells investors in a research note. The analyst sees "no clear winner" in the gene editing patent debate.

TODAY'S FREE FLY STORIES

BLUE

bluebird bio

$171.15

3.25 (1.94%)

20:25
12/10/17
12/10
20:25
12/10/17
20:25
Conference/Events
bluebird bio to hold a webcast »

Management provides a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

  • 14

    Dec

DIS

Disney

$104.23

-0.19 (-0.18%)

, GOOG

Alphabet

$1,037.05

6.12 (0.59%)

20:06
12/10/17
12/10
20:06
12/10/17
20:06
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

DIS

Disney

$104.23

-0.19 (-0.18%)

GOOG

Alphabet

$1,037.05

6.12 (0.59%)

GOOGL

Alphabet Class A

$1,049.38

4.81 (0.46%)

DAL

Delta Air Lines

$53.46

0.05 (0.09%)

BRK.A

Berkshire Hathaway

$294,385.33

285.33 (0.10%)

VLKAY

Volkswagen

$40.10

0.6 (1.52%)

PXD

Pioneer Natural

$155.90

1.65 (1.07%)

AMAT

Applied Materials

$51.43

-0.87 (-1.66%)

EPD

Enterprise Products

$24.94

0.25 (1.01%)

ALLY

Ally Financial

$28.65

0.28 (0.99%)

ANTM

Anthem

$224.85

1.21 (0.54%)

USFD

US Foods

$31.00

0.38 (1.24%)

TJX

TJX

$73.88

0.04 (0.05%)

ROST

Ross Stores

$76.89

0.19 (0.25%)

MBI

MBIA

$8.08

-0.01 (-0.12%)

CVS

CVS Health

$73.09

2 (2.81%)

T

AT&T

$36.73

0.56 (1.55%)

DISH

Dish

$48.59

-0.36 (-0.74%)

SNE

Sony

$45.79

0.04 (0.09%)

FOX

21st Century Fox

$32.97

-0.8 (-2.37%)

FOXA

21st Century Fox

$33.30

-0.88 (-2.57%)

TM

Toyota

$124.45

1.06 (0.86%)

SFTBY

SoftBank

$41.62

-0.02 (-0.05%)

GGP

GGP

$23.43

0.03 (0.13%)

BPY

Brookfield Property

$21.61

0.08 (0.37%)

HCA

HCA Healthcare

$84.84

-0.22 (-0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 14

    Dec

  • 14

    Dec

  • 09

    Jan

  • 23

    Jan

  • 07

    Feb

  • 18

    Mar

  • 08

    May

AKTX

Akari Therapeutics

$4.90

-0.14 (-2.78%)

19:25
12/10/17
12/10
19:25
12/10/17
19:25
Conference/Events
Akari Therapeutics to hold an investor and analyst event »

In conjunction with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

BMRN

BioMarin

$81.99

1.09 (1.35%)

, ALXN

Alexion

$114.46

7.68 (7.19%)

19:11
12/10/17
12/10
19:11
12/10/17
19:11
Recommendations
BioMarin, Alexion, Celgene analyst commentary at Piper Jaffray »

Piper Jaffray remains…

BMRN

BioMarin

$81.99

1.09 (1.35%)

ALXN

Alexion

$114.46

7.68 (7.19%)

CELG

Celgene

$106.09

3.36 (3.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

  • 08

    Jan

  • 18

    Jan

  • 28

    Feb

  • 25

    Mar

TWX

Time Warner

$90.71

0.34 (0.38%)

, CMCSA

Comcast

$37.95

0.06 (0.16%)

18:50
12/10/17
12/10
18:50
12/10/17
18:50
Hot Stocks
Box Office Battle: 'Coco' stays number 1 with $18.3M »

Disney (DIS) and…

TWX

Time Warner

$90.71

0.34 (0.38%)

CMCSA

Comcast

$37.95

0.06 (0.16%)

CMCSK

Comcast

SNE

Sony

$45.79

0.04 (0.09%)

FOX

21st Century Fox

$32.97

-0.8 (-2.37%)

FOXA

21st Century Fox

$33.30

-0.88 (-2.57%)

LGF.A

Lionsgate

$31.56

-0.07 (-0.22%)

DIS

Disney

$104.23

-0.19 (-0.18%)

VIAB

Viacom

$29.29

-0.35 (-1.18%)

VIA

Viacom

$34.00

-0.25 (-0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

VLKAY

Volkswagen

$40.10

0.6 (1.52%)

18:38
12/10/17
12/10
18:38
12/10/17
18:38
Periodicals
Volkswagen CEO suggests ending diesel vehicles subsidies, NY Times reports »

Volkswagen CEO said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCA

HCA Healthcare

$84.84

-0.22 (-0.26%)

18:35
12/10/17
12/10
18:35
12/10/17
18:35
Periodicals
Hospital giants in talks to merge, WSJ reports »

Ascension and Providence…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLKAY

Volkswagen

$40.10

0.6 (1.52%)

18:27
12/10/17
12/10
18:27
12/10/17
18:27
Periodicals
Volkswagen executive may ask to serve sentence in Germany, Reuters says »

Volkswagen executive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GGP

GGP

$23.43

0.03 (0.13%)

, BPY

Brookfield Property

$21.61

0.08 (0.37%)

18:21
12/10/17
12/10
18:21
12/10/17
18:21
Periodicals
Mall owner GGP rejects Brookfield Property buyout offer, Reuters reports »

U.S. mall owner GGP (GGP)…

GGP

GGP

$23.43

0.03 (0.13%)

BPY

Brookfield Property

$21.61

0.08 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATRC

AtriCure

$17.96

0.01 (0.06%)

18:16
12/10/17
12/10
18:16
12/10/17
18:16
Recommendations
AtriCure analyst commentary at Piper Jaffray »

Piper Jaffray remains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

KPTI

Karyopharm

$11.11

0.48 (4.52%)

18:11
12/10/17
12/10
18:11
12/10/17
18:11
Hot Stocks
Karyopharm presents positive phase 1/2 Eltanexor data »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KPTI

Karyopharm

$11.11

0.48 (4.52%)

18:09
12/10/17
12/10
18:09
12/10/17
18:09
Hot Stocks
Karyopharm presents positive Selinexor data from STOMP study »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGIO

Agios Pharmaceuticals

$60.97

0.14 (0.23%)

18:05
12/10/17
12/10
18:05
12/10/17
18:05
Hot Stocks
Agios Pharmaceuticals presents updated data from DRIVE PK study »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

ICL

ICL

$4.03

-0.07 (-1.71%)

18:01
12/10/17
12/10
18:01
12/10/17
18:01
Hot Stocks
ICL completes sale of 50% share of IDE Technologies for $167M »

ICL announced that it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$32.74

0.52 (1.61%)

17:52
12/10/17
12/10
17:52
12/10/17
17:52
Hot Stocks
AstraZeneca Calquence shows potential in chronic lymphocytic leukemia trials »

AstraZeneca and Acerta…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZIOP

Ziopharm

$4.43

0.09 (2.07%)

, XON

Intrexon

$13.28

0.16 (1.22%)

17:48
12/10/17
12/10
17:48
12/10/17
17:48
Hot Stocks
Ziopharm announces presentation of data from T-Cell Therapy programs »

Ziopharm Oncology (ZIOP)…

ZIOP

Ziopharm

$4.43

0.09 (2.07%)

XON

Intrexon

$13.28

0.16 (1.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLUE

bluebird bio

$171.15

3.25 (1.94%)

17:45
12/10/17
12/10
17:45
12/10/17
17:45
Hot Stocks
bluebird bio announces results from LentiGlobin study in Severe Sickle Cell »

bluebird bio announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

  • 14

    Dec

BLUE

bluebird bio

$171.15

3.25 (1.94%)

17:37
12/10/17
12/10
17:37
12/10/17
17:37
Hot Stocks
bluebird bio presents new data from clinical studies of LentiGlobin Gene Therapy »

bluebird bio announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

  • 14

    Dec

VSTM

Verastem

$4.33

0.36 (9.07%)

17:35
12/10/17
12/10
17:35
12/10/17
17:35
Hot Stocks
Verastem announces phase 3 DUO study met primary endpoint »

Verastem announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

CELG

Celgene

$106.09

3.36 (3.27%)

, BLUE

bluebird bio

$171.15

3.25 (1.94%)

17:30
12/10/17
12/10
17:30
12/10/17
17:30
Hot Stocks
Celgene, bluebird bio announce updated results from CRB-401 Phase 1 study »

Celgene (CELG) and…

CELG

Celgene

$106.09

3.36 (3.27%)

BLUE

bluebird bio

$171.15

3.25 (1.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

  • 10

    Dec

  • 14

    Dec

  • 18

    Jan

  • 25

    Mar

GILD

Gilead

$74.22

1.5 (2.06%)

17:22
12/10/17
12/10
17:22
12/10/17
17:22
Hot Stocks
Kite announces long-term data from pivotal ZUMA-1 study of Yescarta »

Kite, a Gilead company,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Feb

EPZM

Epizyme

$13.25

0.25 (1.92%)

17:18
12/10/17
12/10
17:18
12/10/17
17:18
Hot Stocks
Epizyme presents new biomarker data on Tazemetostat »

Epizyme announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIVV

Bioverativ

$51.47

0.76 (1.50%)

17:16
12/10/17
12/10
17:16
12/10/17
17:16
Hot Stocks
Study shows Bioverativ Eloctate has potential to improve bleed protection »

Bioverativ and Swedish…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYRS

Syros Pharmaceuticals

$12.37

-0.505 (-3.92%)

17:04
12/10/17
12/10
17:04
12/10/17
17:04
Hot Stocks
Syros Pharmaceuticals announces new preclinical data on SY-1365 »

Syros Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

SYRS

Syros Pharmaceuticals

$12.37

-0.505 (-3.92%)

17:00
12/10/17
12/10
17:00
12/10/17
17:00
Hot Stocks
Syros Pharmaceuticals announces initial data from phase 2 trial of SY-1425 »

Syros Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.